SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Sun Yat-sen — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientSun Yat-sen
Date of birth1866-11-12
IdentifiersMRN HR-ET016-SYN-TD; SSN (made up) 000-16-4183
Document date1924-06-01
AuthorWen-Li Huang, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Staging laparoscopy result, tumor board recommendation, and first cycle of treatment. [S]

History of Present Illness

Mr. Sun returns two weeks after the consultation and five days after the staging laparoscopy. At laparoscopy the surgeon found several small nodules on the lining of the abdomen and the omentum, and their biopsy shows adenocarcinoma of the same type. The tumor board met two days later and advised against an operation and for chemoimmunotherapy. He has recovered from the laparoscopy; the port and the small wounds are healing. The ache under his ribs is unchanged at 2 of 10. He said he had expected this, as a physician, but found it hard to hear. He has slept poorly for several nights. He wants to start treatment today if he is fit for it and asked how long treatment might keep him working. [S]

ElementDetail
Staging laparoscopyPeritoneal and omental nodules; biopsy adenocarcinoma
Tumor boardNot resectable; first-line chemoimmunotherapy advised
RecoveryWounds and port healing
Mood and sleepFinds the news hard; sleeping poorly
His questionHow long treatment may keep him working

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; weight 60.0 kg; no fever
GastrointestinalPositiveAche under the right ribs 2 of 10; no jaundice or vomiting
PsychiatricPositiveLow at times and sleeping poorly since the result; no thoughts of self-harm
IntegumentaryNegativePort and laparoscopy wounds healing without redness

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a dayTwo tablets by mouth every 8 hours as needed, no more than 3,000 mg a dayOral route1924-05-04activeS
Gemcitabine 1,000 mg/m2 (1,660 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cyclesIntravenous route1924-06-01activeS
Cisplatin 25 mg/m2 (41 mg) intravenous infusion on days 1 and 8 of each 21-day cycleDays 1 and 8 of each 21-day cycle, up to 8 cycles, with hydrationIntravenous route1924-06-01activeS
Durvalumab 1,500 mg intravenous infusion on day 1 of each 21-day cycleDay 1 of each 21-day cycle with chemotherapy, then every 4 weeks aloneIntravenous route1924-06-01activeS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet by mouth every 8 hours as needed for nauseaOral route1924-06-01activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1924-06-01Body height165cmS
1924-06-01Body weight60kgS
1924-06-01Body mass index (BMI) [Ratio]22kg/m2S
1924-06-01Systolic blood pressure126mm[Hg]S
1924-06-01Diastolic blood pressure80mm[Hg]S
1924-06-01Heart rate84/minS
1924-06-01Respiratory rate16/minS
1924-06-01Body temperature36.7CelS
1924-06-01Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1924-06-01Leukocytes [#/volume] in Blood by Automated count7.410*3/uL4-11 10*3/uLNormalS
1924-06-01Neutrophils [#/volume] in Blood by Automated count4.910*3/uL1.8-7.7 10*3/uLNormalS
1924-06-01Hemoglobin [Mass/volume] in Blood12.2g/dL13.2-17.1 g/dLLowS
1924-06-01Platelets [#/volume] in Blood by Automated count31810*3/uL150-400 10*3/uLNormalS
1924-06-01Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1924-06-01Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1924-06-01Creatinine [Mass/volume] in Serum or Plasma0.84mg/dL0.74-1.35 mg/dLNormalS
1924-06-01Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1919)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1924-06-01Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.2 mg/dLNormalS
1924-06-01Albumin [Mass/volume] in Serum or Plasma3.4g/dL3.5-5 g/dLLowS
1924-06-01Bilirubin.total [Mass/volume] in Serum or Plasma0.8mg/dL0.2-1.2 mg/dLNormalS
1924-06-01Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma236U/L40-129 U/LHighS
1924-06-01Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma52U/L10-40 U/LHighS
1924-06-01Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma44U/L7-55 U/LNormalS
1924-06-01Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
1924-06-01Cancer Ag 19-9 [Units/volume] in Serum or Plasma498U/mL<=35 U/mLHighS
1924-06-01Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1924-06-01ECOG Performance Status score1{score}S

Physical Exam

Vital signs recorded on 1924-06-01; see the Vital Signs section. [S]

SystemFinding
GeneralThin, composed; blood pressure 126/80, pulse 84; weight 60.0 kg; no jaundice
AbdomenHealing laparoscopy wounds; mass 4 cm below the right costal margin, unchanged; no ascites
Chest wallPort site clean and dry
Ears, nose, mouth, and throatHears a whispered voice in both ears

Problems

ProblemClinical statusVerificationCodeProvenance
Right upper quadrant abdominal mass with weight loss: a dull ache under the right ribs and early fullness for about three months, 4 kg weight loss, and a firm, non-tender mass felt 4 cm below the right costal margin; no jaundice, fever, or itching. Ultrasound today: a 6.8 cm solid, heterogeneous mass in liver segments IV and V that cannot be separated from the gallbladder, which contains stones; the rest of the liver is smooth, with no ascites. Multiphase CT, tumor markers, hepatitis serology and medical oncology consultation arrangedresolvedconfirmed R19.01S — Synthetic presenting problem anchored to the documented right upper abdominal mass; superseded by the biopsy diagnosis.
Adenocarcinoma of the gallbladder invading the liver: core biopsy of the liver mass shows moderately differentiated adenocarcinoma (CK7 positive, CK20 and CDX2 negative), and multiphase CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged nodes in the hepatoduodenal ligament; no cirrhosis; alpha-fetoprotein normal, CA 19-9 raised. Clinical T3 N1 before staging laparoscopy (AJCC 8th edition). Synthetic modern episode linked to his documented final illness, described in life as liver cancer and at autopsy as gallbladder adenocarcinomaactiveconfirmed C23S — Synthetic modern diagnosis chosen to fit the documented findings: a mass involving the liver at operation and gallbladder adenocarcinoma at autopsy.
Resolved hepatitis B infection: hepatitis B surface antigen negative, total core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative. At risk of reactivation during chemotherapy and immunotherapy; monitoredactiveconfirmed Z86.19S — Synthetic serology; not a claim that he had hepatitis B in his lifetime. No fetched source mentions hepatitis.
Peritoneal metastases from gallbladder adenocarcinoma: several 3 to 6 mm nodules on the parietal peritoneum and omentum at staging laparoscopy, biopsy positive for adenocarcinoma of the same type; stage IVB (M1), not resectableactiveconfirmed C78.6S — Synthetic finding anchored to the peritoneal metastases reported at autopsy.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingStaging laparoscopyBefore resection of gallbladder cancerCompleted todayPeritoneal and omental nodules; biopsy adenocarcinoma: M1
ReferralMultidisciplinary tumor boardBefore treatment, and when the stage changesCompleted todayNot resectable; gemcitabine, cisplatin and durvalumab advised
ImagingCT of the chest, abdomen and pelvisAt staging, then every 2 to 3 months on treatmentDueBaseline from staging; restaging after three cycles
LaboratoryCA 19-9 (and CEA when raised)At diagnosis, then with each cycle or restagingCompleted todayCA 19-9 498 U/mL at baseline
LaboratoryBlood count with neutrophilsBefore every dose (days 1 and 8)Completed todayWhite cells 7.4, neutrophils 4.9, hemoglobin 12.2 g/dL, platelets 318
LaboratoryCreatinine and eGFRBefore every dose (days 1 and 8)Completed todayCreatinine 0.84 mg/dL, eGFR 102; adequate for cisplatin
LaboratoryMagnesium and potassiumBefore every dose (days 1 and 8)Completed todayMagnesium 2.0 mg/dL, potassium 4.3 mmol/L, sodium 137 mmol/L
LaboratoryLiver tests (bilirubin, alkaline phosphatase, AST, ALT, albumin)Before every dose (days 1 and 8)Completed todayBilirubin 0.8 mg/dL, alkaline phosphatase 236, AST 52, ALT 44 U/L, albumin 3.4 g/dL
LaboratoryTSHBaseline, then every 4 to 6 weeks on durvalumabCompleted today1.9 mIU/L at baseline
LaboratoryGlucoseBaseline, then with each pre-dose chemistry panel on durvalumabDeferredMissed: today's pre-treatment panel was ordered as a renal panel with magnesium and did not include glucose. Glucose was 98 mg/dL at intake and he has no thirst or excess urination, so no harm is apparent. Corrective action: glucose added to the standing pre-dose order from the next draw
LaboratoryHBV DNA and ALT (resolved hepatitis B)Every 3 months during treatment and for 6 to 12 months afterUp to dateHBV DNA undetectable before treatment; ALT 44 U/L today (liver tests above); next in 2 to 3 months
ExaminationHearing (cisplatin)Baseline before cisplatin, then by symptoms each cycleDeferredMissed: no baseline audiogram before the first cisplatin dose; whispered-voice test normal today and no hearing symptoms. The lower 25 mg/m2 dose carries less risk; corrective action is to ask about hearing at each cycle and obtain an audiogram for any change
SurveyECOG performance statusEvery visitCompleted todayECOG 1
ExaminationWeight and nutritionEvery visitCompleted today60.0 kg; dietitian advice followed
SurveyPainEvery visitCompleted today2 of 10 on acetaminophen
SurveyDistress and depression (PHQ-9)At diagnosis and at each change in treatmentCompleted todayPHQ-9 6, mild; no thoughts of self-harm
LaboratoryComprehensive genomic profiling of tumor tissueAt diagnosis of advanced diseaseOrderedPending
ReferralSpecialist palliative careFrom the diagnosis of advanced cancerReferredFirst visit next week
Medication safetyImmune-related side effects (diarrhea, rash, cough or breathlessness, fatigue, endocrine symptoms)Teaching before the first dose, then every visitCompleted todayTaught today with written information

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026); Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1) (2022); Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021)

Follow-up: Cycle 1 day 8 next week; palliative care next week. Visit before cycle 4 with a restaging CT. Next scheduled visit 1924-08-03: before cycle 4: restaging CT, tumor marker, toxicity review, hepatitis B monitoring, and genomic profiling result. [S]